-
Published04/11/2024
-
Deadline02/12/2024
-
Opening of tenders02/12/2024
-
Today12/12/2024
Utilities
- indicates text translated automatically in your browsing language
Medicinal product with the active substance FREMANEZUMAB Text automatically translated in your browsing language Automatically translated
The subject of the contract is to ensure the continuous supply of medicinal products ATC group N02CD03 with the active substance Fremanezumab in accordance with the technical requirements of the contracting authority and with the contractual and other conditions specified in the tender documentation. Text automatically translated in your browsing language Automatically translated
https://zakazky.pardubickykraj.cz/profile_display_1965.html
https://zakazky.pardubickykraj.cz/profile_display_1965.html
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.